A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the progression of type 1 diabetes (T1D).
Tumor microenvironment (TME) has been regarded as a critical regulating environment for immune response and tumor growth in recent years. Similar to the interaction between seeds and soil, TME ...
A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
14don MSN
Study links stroke-induced stress response to weakened immune system and higher infection risk
A new University of Manchester and Edinburgh study published in the journal Brain, Behavior and Immunity has found that people who have had a stroke have fewer of a specific type of immune cell called ...
Zenas BioPharma announced advancements in the clinical development of obexelimab, a novel CD-19 x FcγRIIb inhibitor targeting B cell function, with key trial results expected in 2025. The Phase 2 ...
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results